bioMérieux SA logo

bioMérieux SA (BIM)

Market Closed
10 Jun, 15:30
XPAR XPAR
70. 15
-1.15
-1.6129%
11.72B Market Cap
- P/E Ratio
3.64% Div Yield
150,498 Volume
- Eps
71.3
Previous Close
Add Transaction
Day Range
69.95 71.75
Year Range
68.05 128.3
Want to track BIM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BIM closed today lower at €70.15, a decrease of -1.6129% from yesterday's close, completing a monthly decrease of -2.5694% or -€1.85. Over the past 12 months, BIM stock lost -36.4007%.
BIM pays dividends to its shareholders, with the most recent payment made on 4 hours ago. The next payment will be today for a total of €0.98.
The last earnings report, released on Feb 27, 2026, missed the consensus estimates by -2.34%. On average, the company has fell short of earnings expectations by -1.06%, based on the last three reports.
bioMérieux SA has completed 1 stock splits, with the recent split occurring on Sep 20, 2017.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on LSE (EUR).

BIM Chart

People also search for

SAF
Safran SA
291.5
-1.387%
SGO
Compagnie de Saint-Gobain S.A.
74.32
-1.5107%
EN
Bouygues SA
48.89
+0.6588%

bioMérieux SA (BIM) FAQ

What is the stock price today?

The current price is €70.15.

On which exchange is it traded?

bioMérieux SA is listed on XPAR.

What is its stock symbol?

The ticker symbol is BIM.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.64%.

What is its market cap?

As of today, the market cap is 11.72B.

Has bioMérieux SA ever had a stock split?

bioMérieux SA had 1 splits and the recent split was on Sep 20, 2017.

bioMérieux SA Profile

Professional Services Industry
Industrials Sector
Pierre Boulud CEO
XPAR Exchange
FR0013280286 ISIN
FR Country
14,147 Employees
9 Jun 2025 Last Dividend
20 Sep 2017 Last Split
- IPO Date

Overview

bioMérieux S.A., originally known as B-D Mérieux, is a global leader in the development and production of in vitro diagnostic solutions, with a history dating back to 1963. Headquartered in Marcy-l'Étoile, France, the company operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. Its main focus is on diagnosing infectious diseases, leveraging biological samples such as blood, saliva, and urine to detect a variety of bacterial, parasitic, and viral infections. Additionally, bioMérieux extends its expertise to the microbiological control of production environments in the food, pharmaceutical, and cosmetic industries, ensuring safety and compliance. A subsidiary of Institut Mérieux SA, bioMérieux S.A. serves a wide range of clients including clinical and hospital laboratories, physicians, blood banks, veterinarians, and industrial control laboratories, underlining its integral role in global health and safety industries.

Products and Services

  • In Vitro Diagnostic Solutions:

    bioMérieux's core offerings include systems designed for the diagnosis of infectious diseases. Utilizing biological samples, these systems can accurately diagnose a wide array of infections, from bacterial and parasitic to viral, ensuring timely and effective patient care.

  • Microbiological Control Solutions:

    For industries such as food, pharmaceutical, and cosmetics, bioMérieux provides solutions to monitor and control the microbiological quality of production processes and environments. This not only helps in ensuring product safety but also in adhering to regulatory standards.

  • BIOMÉRIEUX VISION SUITE:

    This suite of software products and services is designed to collect, analyze, and merge various sources of data for informed decision-making. It exemplifies bioMérieux's commitment to advancing healthcare through technological innovation.

  • Instrumentation and Software Design and Maintenance:

    The company excels in the design, manufacture, and maintenance of instruments and software that are essential for conducting in vitro diagnostic tests. This ensures reliability and accuracy in diagnostics, which are critical for patient care.

  • Reagent Design and Manufacturing:

    bioMérieux also designs and manufactures reagents necessary for in vitro diagnostic tests. These high-quality reagents are crucial for the accuracy and reliability of diagnostic results, underpinning the company's reputation in healthcare diagnostics.

Contact Information

Address: 376 Chemin De l’Orme
Phone: 33 4 78 87 20 00